ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Virginia » Rheumatology

Top Rheumatology Prescribers in Virginia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
NANDINI CHHITWAL MD

Rheumatology

565

$95.4K

87
51 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

11%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

27%
prescriptions for brand name drugs

Avg: 24%

$169
Average prescription price

Avg: $132

ROSALIA LOMEO M.D.

Rheumatology

1,524

$226K

101
56 are 65+

25%
patients receiving schedule two controlled substances

Avg: 4%

27%
patients receiving schedule three controlled substances

Avg: 9%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$148
Average prescription price

Avg: $132

SERGIO LEON M.D.

Rheumatology

1,368

$177K

201
115 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$129
Average prescription price

Avg: $132

MOHSEN GHAFOURI MD

Rheumatology

2,408

$303K

487
405 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

4%
patients receiving schedule three controlled substances

Avg: 9%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

36%
prescriptions for brand name drugs

Avg: 24%

$126
Average prescription price

Avg: $132

ADEGBENGA BANKOLE M.D.

Rheumatology

2,178

$233K

308
203 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$107
Average prescription price

Avg: $132

MALGORZATA GRADZKA M.D.

Rheumatology

681

$201K

97
78 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

31%
prescriptions for brand name drugs

Avg: 24%

$295
Average prescription price

Avg: $132

MARTHA BARNETT M.D.

Rheumatology

1,027

$168K

111
82 are 65+

12%
patients receiving schedule two controlled substances

Avg: 4%

14%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 24%

$164
Average prescription price

Avg: $132

DON MARTIN M.D.

Rheumatology

4,071

$549K

357
253 are 65+

4%
patients receiving schedule two controlled substances

Avg: 4%

10%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$135
Average prescription price

Avg: $132

ROBERT JOHNSON M.D.

Rheumatology

3,804

$438K

393
216 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

19%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 24%

$115
Average prescription price

Avg: $132

ALBERT LEE M.D.

Rheumatology

1,673

$193K

217
150 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

8%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

27%
prescriptions for brand name drugs

Avg: 24%

$115
Average prescription price

Avg: $132

PARITA VASA MD

Rheumatology

646

$54.8K

125
95 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 24%

$85
Average prescription price

Avg: $132

JOHN MELTON M.D.

Rheumatology

1,531

$120K

146
116 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

14%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 24%

$79
Average prescription price

Avg: $132

ANDRONIKI BILI M.D.

Rheumatology

1,559

$343K

202
142 are 65+

7%
patients receiving schedule two controlled substances

Avg: 4%

12%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 24%

$220
Average prescription price

Avg: $132

JANE DERRIG DO

Rheumatology

4,891

$714K

499
369 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

6%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$146
Average prescription price

Avg: $132

MATTHEW HOGENMILLER MD

Rheumatology

2,595

$223K

294
189 are 65+

9%
patients receiving schedule two controlled substances

Avg: 4%

18%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 24%

$86
Average prescription price

Avg: $132

JOSEPH LEMMER MD

Rheumatology

11,798

$1.12M

888
511 are 65+

11%
patients receiving schedule two controlled substances

Avg: 4%

21%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 24%

$95
Average prescription price

Avg: $132

KANAN MANIAR M.D.

Rheumatology

736

$131K

143
119 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

10%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

29%
prescriptions for brand name drugs

Avg: 24%

$178
Average prescription price

Avg: $132

SHIKHA SAREBAHI M.D

Rheumatology

496

$137K

115
79 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

28%
prescriptions for brand name drugs

Avg: 24%

$277
Average prescription price

Avg: $132

SARAH CLARKSON M.D.

Rheumatology

1,570

$306K

212
155 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 24%

$195
Average prescription price

Avg: $132

JULIANNE ORLOWSKI D.O.

Rheumatology

1,532

$208K

243
176 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

23%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$136
Average prescription price

Avg: $132

WILLIAM BLAYLOCK M.D.

Rheumatology

8,119

$898K

435
249 are 65+

12%
patients receiving schedule two controlled substances

Avg: 4%

31%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$111
Average prescription price

Avg: $132

JANET LEWIS

Rheumatology

728

$238K

97
52 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$327
Average prescription price

Avg: $132

MICHAEL STRACHAN M.D.

Rheumatology

5,306

$633K

483
376 are 65+

7%
patients receiving schedule two controlled substances

Avg: 4%

18%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$119
Average prescription price

Avg: $132

STEVEN MAESTRELLO M.D.

Rheumatology

4,955

$425K

500
382 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$86
Average prescription price

Avg: $132

GARRY BAYLISS M.D.

Rheumatology

4,834

$611K

481
363 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$126
Average prescription price

Avg: $132

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank